We respond to the SMC approval of palbociclib with fulvestrant for use on NHS in Scotland

8 July 2019 The Scottish Medicines Consortium (SMC) has today (8 July 2019) announced its decision to approve palbociclib in combination with...

8 July 2019

We respond to the launch of the Interim NHS People Plan

3 June 2019 The new Interim NHS People Plan was launched on Monday 3 June 2019 to address the workforce challenges the health service is...

6 June 2019

We respond to trial showing that ribociclib with an aromatase inhibitor extends life for some premenopausal patients with metastatic breast cancer

Ribociclib (Kisqali, Novartis) is one of a class of drugs known as CDK4/6 inhibitors, which have recently been introduced to NHS care and work by...

3 June 2019

We respond to approval of Abemaciclib for two new treatment options on NHS Scotland

The Scottish Medicines Consortium (SMC) has today (13 May 2019) announced its decision to approve breast cancer drug abemaciclib as part of two new...

13 May 2019

Breast Cancer Care and Breast Cancer Now responds to the National Audit of Breast Cancer in Older Patients 2019 Annual Report

The National Audit of Breast Cancer in Older Patients (NABCOP), carried out by the Royal College of Surgeons and the Association of Breast Surgery,...

10 May 2019

We respond to study suggesting foods containing phenolic acids may help lower breast cancer risk

New research presented at the European Congress on Obesity has suggested that nutrients called phenolic acids – which are found in foods such as...

2 May 2019

We respond to cancer incidence in Scotland

Breast Cancer Care and Breast Cancer Now respond to a report on cancer incidence in Scotland.  Ashleigh Simpson, Policy and Campaigns...

1 May 2019

We respond to NHS Tayside Clinical Risk Assessment Report

The Clinical Risk Assessment report follows a previous report from Health Improvement Scotland which highlighted that patients in NHS Tayside...

17 April 2019

We respond to NICE draft decision to reject ribociclib with fulvestrant for use on the NHS

The National Institute for Health and Care Excellence (NICE) has today (10 April 2019) provisionally rejected breast cancer drug ribociclib in...

10 April 2019